Sign in or register today for access to this and other blogs and discussions.
John Ryan discusses the implications of two new, phase 3 studies of a novel oral pulmonary vasodilator for treating pulmonary hypertension. How do you think the drug — riociguat — will affect the management of PH?
CardioExchange is an online community hosted by the New England Journal of Medicine and NEJM Journal Watch and dedicated to improving cardiac patient care. Membership is free for medical professionals.